Cannabigerol (CBG) is a non-psychoactive cannabinoid found in the Cannabis genus of plants.
Cannabigerol is found in higher concentrations in hemp rather than in varieties of Cannabis cultivated for high THC content and their corresponding psychoactive properties.
Cannabigerol has been found to act as a high affinity α2-adrenergic receptor agonist, moderate affinity 5-HT1A receptor antagonist, and low affinity CB1 receptor antagonist.
It also binds to the CB2 receptor, but whether it acts as an agonist or antagonist at this site is unknown.
Cannabigerol has been shown to relieve interocular pressure, which may be of benefit in the treatment of glaucoma.
Although CBG hasn’t been studied nearly as much as CBD, a small body of evidence suggests it has anti-inflammatory and anti-oxidant effects as well.
Earlier this year (2013) researchers from Italy observed both of these properties in an experimental model of inflammatory bowel disease, concluding that “CBG may represent a new therapeutic opportunity” for patients with the disorder.
Other pre-clinical studies suggest more diverse uses for CBG as a COX-2 inhibitor, similar to the popular group of pharmaceuticals known as non-steroidal anti-inflammatory drugs (NSAIDs).
More research is definitely necessary to determine CBG’s true medical potential, as well as how to utilize it effectively.